MSD
MK4280A (favezelimab+pembro)
Biodrugs/ Drugs
Cancer
A Phase 3 study of MK-4280A [co-formulated favezelimab (MK-4280) plus pembrolizumab (MK-3475)] Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer
3Phase III in Spain,
2Phase II,
1Phase I